KPE-C-103 Executive Program in Global Drug Regulatory Affairs [EPGDRA]
Posted on06 Oct 2018
Comments0
Course Flow –
KPE-C-003 KPE’s Advance Diploma in Drug Regulatory Affairs
Posted on18 Sep 2014
Comments0
Course Flow –
+91 789 2456 581 | info@nckpharma.com
Sign In
|Sign Up
Please sign in first
Not a member?
Please simply create an account before buying/booking any courses.
Create an account for free!
- Home
- NCK services
- Course List
- Executive Program
- Advance Diploma Program
- Advance Diploma Dual Specialization
- Certificate Courses – 1 Month
- Biotech Regulatory Affairs & Strategic Management
- Pharma Product Management
- Pharma Project Management
- Medical Devices Regulation
- Drug Regulatory Affairs
- Latam DRA
- African DRA
- GCC Regulatory Affairs
- ASEAN DRA
- European DRA
- USFDA Regulation
- GMP & GMP Audit
- Dossier Training
- Drug Discovery to Commercialization
- QA Documentation
- IP Management
- Short Courses / Books / White Paper
- In & Out-Licensing in Pharma
- Pharma marketing plan development
- Pharma Visual Aid Development Training
- Data Integrity Training
- ANDA Submission Process
- Fundamental Training on Drug Regulatory Affairs
- DMF Preparation & Submission
- Regulatory Strategic Planning
- Export Documentation
- 505(b)(2) Application Submission
- Admission Process
- Features of Online Courses
- Course Catalogue
- Course Application form
- Admission Notification & Special Offers
- Frequently asked question related to KPE courses
- Prospect Identification Process
- Final Examination Registration
- How to change / reset password?
- Verify Course Certificate
- Request for Course Completion Certificate
- Knowledge Base
- Contact
KPE-C-103 Executive Program in Global Drug Regulatory Affairs [EPGDRA]
Our Popular Courses
Recent Articles
- Top 10 Global Pharmaceutical Company in 2018
- Take a self competency test in authorized generics
- GSK’s Shingrix received chinese approval for shingles vaccine
- Bayer to launch Baycox Iron injection combination in Europe
- Health Canada approves Biocon and Mylan’s trastuzumab biosimilar ‘Ogivri’ for HER2-positive cancers
- Case Study – A close look into Eli Lilly’s pricing strategy for Insulin Lispro injection in US market
- Takeda, Frazier Healthcare Partners to launch Phathom Pharma
- Can a new drug rejected by USFDA, can get EU approval?
- Novatis’s Xiidra acquisition from Takeda for USD 5.3 billion
- FDA approval of first medical device for treatment of ADHD